2-溴-6-氯吡嗪 | 916791-07-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-溴-6-氯吡嗪
• 英文名称: 2-bromo-6-chloropyrazine
• CAS: 916791-07-6
• 化学式: C₄H₂BrClN₂
• 分子量: 193.43
• InChiKey: UZAXEXBMDHIXNU-UHFFFAOYSA-N

物化性质

• 沸点：
  210.5±35.0℃ (760 Torr)
• 密度：
  1.859±0.06 g/cm3 (20 ºC 760 Torr)
• 闪点：
  81.1±25.9℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Bromo-6-chloropyrazine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-6-chloropyrazine
CAS number: 916791-07-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H2BrClN2
Molecular weight: 193.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  邻苯二甲酸二甲酯 、 2-溴-6-氯吡嗪 在 正丁基锂 作用下， 以 乙醚 为溶剂， 反应 3.0h， 以60%的产率得到methyl 2-(6-chloropyrazin-2-carbonyl)benzoate
  参考文献：
  名称：

  一种芳杂环化合物及其制备方法以及一种有机电致发光器件

  摘要：

  本发明提供了一种芳杂环化合物，具有式(Ⅰ)所示结构。本发明在苯并[g]喹喔啉，苯并[g]喹啉及苯并[g]异喹啉等结构中引进R1、R2、R3，可提高电子密度、向上技能及改善化合物性能，从而使式(I)所示的芳杂环化合物可以作为很好的电子传输材料应用，以其制备的有机电致发光器件具备较高的亮度、较好的耐热性、长寿命及较高的发光效率等特点。

  公开号：

  CN105693631A

文献信息

• [EN] 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS<br/>[FR] COMPOSÉS 2-HÉTÉROCYCLYLAMINO PYRAZINES SUBSTITUÉES EN POSITION 6 EN TANT QU'INHIBITEURS DE CHK-1
  申请人：PFIZER

  公开号：WO2010016005A1

  公开（公告）日：2010-02-11

  The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, their synthesis, and their use as CHK-1 inhibitors.

  本发明涉及式(I)的化合物，及其药用可接受的盐，它们的合成以及它们作为CHK-1抑制剂的用途。
• Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents
  作者：Allyn T. Londregan、Liuqing Wei、Jun Xiao、Nathanael G. Lintner、Donna Petersen、Robert G. Dullea、Kim F. McClure、Michael W. Bolt、Joseph S. Warmus、Steven B. Coffey、Chris Limberakis、Julien Genovino、Benjamin A. Thuma、Kevin D. Hesp、Gary E. Aspnes、Benjamin Reidich、Christopher T. Salatto、Jeffrey R. Chabot、Jamie H. D. Cate、Spiros Liras、David W. Piotrowski

  DOI：10.1021/acs.jmedchem.8b00650

  日期：2018.7.12

  The optimization of a new class of small molecule PCSK9 mRNA translation inhibitors is described. The potency, physicochemical properties, and off-target pharmacology associated with the hit compound (1) were improved by changes to two regions of the molecule. The last step in the synthesis of the congested amide center was enabled by three different routes. Subtle structural changes yielded significant

  描述了新型小分子PCSK9 mRNA翻译抑制剂的优化。通过改变分子的两个区域，与命中化合物（1）相关的效力，理化性质和脱靶药理作用得到改善。拥挤的酰胺中心合成的最后一步是通过三种不同的途径实现的。细微的结构变化导致药理学和脱靶范围的显着变化。这些努力导致鉴定具有适合体内评估的总体概况的7l和7n。在一项为期14天的毒理学研究中，7l的安全性优于铅7f。我们假设改善的安全性与7l与非翻译核糖体的结合减少以及由于7l脱靶蛋白质的低强度导致的转录选择性的明显改善有关。
• [EN] INDAZOLE CONTAINING MACROCYCLES AND THERAPEUTIC USES THEREOF<br/>[FR] MACROCYCLES CONTENANT DE L'INDAZOLE ET UTILISATIONS THÉRAPEUTIQUES ASSOCIÉES
  申请人：SAMUMED LLC

  公开号：WO2019241540A1

  公开（公告）日：2019-12-19

  Indazole macrocycle compounds of formula (I) for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole macrocycle compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. Formula (I)

  公开了用于治疗各种疾病和病理的Indazole大环化合物的化学式（I）。更具体地，本发明涉及使用Indazole大环化合物或其类似物治疗由Wnt途径信号激活所特征的疾病（例如癌症、异常细胞增殖、血管生成、纤维化疾病、骨骼或软骨疾病和骨关节炎），调节由Wnt途径信号介导的细胞事件，以及由于Wnt途径和/或一个或多个Wnt信号组分的突变或失调而导致的遗传疾病和神经病理/疾病/疾病。还提供了治疗与Wnt相关疾病状态的方法。化学式（I）
• Metal-free arylation of pyrimidines through a photochemical process
  作者：Jonas Ruch、Ariane Aubin、Guillaume Erbland、Audrey Fortunato、Jean-Philippe Goddard

  DOI：10.1039/c5cc08927a

  日期：——

  The photochemical arylation of pyrimidines and pyrazines proceeds smoothly under moderate UVA irradiation and allows us to obtain high-value biaryl compounds through radical intermediates.

  嘧啶和吡嗪的光化芳基化在中等UVA照射下顺利进行，并且通过自由基中间体使我们能够获得高附加值的联芳烃化合物。
• [EN] ANTIBACTERIAL BASIC BIAROMATIC DERIVATIVES WITH AMINOALKOXY SUBSTITUTION<br/>[FR] DÉRIVÉS BI-AROMATIQUES DE BASE ANTIBACTÉRIENS AVEC SUBSTITUTION AMINOALCOXY
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2016059097A1

  公开（公告）日：2016-04-21

  The invention relates to antibacterial compounds of formula I wherein R1a, R2a, R2b, R3a, R3b, R4, R5, U1, U2, U3, U4, V1, V2, V3, V4, X and Q and n are as defined in the specification. It further relates pharmaceutical compositions containing these compounds and the uses of these compounds in the manufacture of medicaments for the treatment of bacterial infections. These compounds are useful antimicrobial agents effective against a variety of human and veterinary pathogens including among others Gram-positive and Gram-negative aerobic and anaerobic bacteria.

  该发明涉及式I的抗菌化合物，其中R1a、R2a、R2b、R3a、R3b、R4、R5、U1、U2、U3、U4、V1、V2、V3、V4、X和Q以及n如规范中所定义。它进一步涉及含有这些化合物的药物组合物，以及这些化合物在制造用于治疗细菌感染的药物品的用途。这些化合物是有用的抗微生物剂，对包括革兰氏阳性和阴性厌氧细菌在内的各种人类和兽医病原体具有有效作用。